Activity of Ertapenem (MK-0826) versus Enterobacteriaceae with Potent β-Lactamases
Open Access
- 1 October 2001
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (10), 2831-2837
- https://doi.org/10.1128/aac.45.10.2831-2837.2001
Abstract
Ertapenem (MK-0826; L-749,345), a new carbapenem with a long serum half-life, was tested, in vitro, against β-lactamase-producing bacteria. The new compound had a MIC at which 90% of the isolates were inhibited of 0.06 μg/ml for extended-spectrum β-lactamase (ESBL)-producing klebsiellas, compared with 0.5 μg/ml for imipenem, 16 μg/ml for cefepime, and >128 μg/ml for ceftazidime and piperacillin-tazobactam. MICs of ertapenem for AmpC-derepressed mutant Enterobacteriaceae were 0.015 to 0.5 μg/ml, whereas imipenem MICs were 0.25 to 1 μg/ml and those of cefepime were 0.5 to 4 μg/ml, and resistance to ceftazidime and piperacillin-tazobactam was generalized. Despite this good activity, the MICs of ertapenem for ESBL-positive klebsiellas mostly were two- to fourfold above those for ESBL-negative strains, and the MICs for AmpC-hyperproducing Enterobacter cloacae and Citrobacter freundii mutants exceeded those for the corresponding AmpC-basal mutants. These differentials did not increase when the inoculum was raised from 10 4 to 10 6 CFU/spot, contraindicating significant lability. Carbapenemase producers were also tested. The IMP-1 metallo-β-lactamase conferred substantial ertapenem resistance (MIC, 128 μg/ml) in a porin-deficient Klebsiella pneumoniae strain, whereas a MIC of 6 μg/ml was recorded for its porin-expressing revertant. SME-1 carbapenemase was associated with an ertapenem MIC of 2 μg/ml for Serratia marcescens S6, compared with Serratia strains lacking this enzyme. In summary, ertapenem had good activity against strains with potent β-lactamases, except for those with known carbapenemases.This publication has 25 references indexed in Scilit:
- Characterization of OXA-25, OXA-26, and OXA-27, Molecular Class D β-Lactamases Associated with Carbapenem Resistance in Clinical Isolates of Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2001
- Complexity and Diversity of Klebsiella pneumoniae Strains with Extended-Spectrum β-Lactamases Isolated in 1994 and 1996 at a Teaching Hospital in Durban, South AfricaAntimicrobial Agents and Chemotherapy, 2001
- Carbapenemases: a problem in waiting?Current Opinion in Microbiology, 2000
- Amino Acid Substitutions in a Variant of IMP-1 Metallo-β-LactamaseAntimicrobial Agents and Chemotherapy, 2000
- OXA-24, a Novel Class D β-Lactamase with Carbapenemase Activity in an Acinetobacter baumannii Clinical StrainAntimicrobial Agents and Chemotherapy, 2000
- Sequence Analysis of ARI-1, a Novel OXA β-Lactamase, Responsible for Imipenem Resistance in Acinetobacter baumannii 6B92Antimicrobial Agents and Chemotherapy, 2000
- Carbapenems: the pinnacle of the beta-lactam antibiotics or room for improvement?Journal of Antimicrobial Chemotherapy, 2000
- Antibiotic resistance and production of extended-spectrum β-Mactamases amongst Klebsiella spp. from intensive care units in EuropeJournal of Antimicrobial Chemotherapy, 1996
- Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistanceAntimicrobial Agents and Chemotherapy, 1994
- In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanismsJournal of Antimicrobial Chemotherapy, 1994